Method of preparing-3-(benzoyl)-oxyrancarboxamides

专利摘要:
Novel trans-isomers of 3-(benzoyl)oxiranecarboxamides, useful as lipogenesis inhibitors in warm-blooded animals.
公开号:SU820662A3
申请号:SU782592451
申请日:1978-03-17
公开日:1981-04-07
发明作者:Бернард Карр Джон；Грэхем Дурхам Хэрри
申请人:Шелл Интернэшнл Рисерч Маатсхаппий Б.В. (Фирма)；
IPC主号:

专利说明:

mol eq of hydrogen peroxide in the presence of 2.8 mol.% alkali metal hydroxide at a temperature of 25-50 C. Acrylamide is obtained by treating the corresponding 3- (benzoyl) acrylic acid with a small excess (5-20%) of phosphorus pentachloride in a suitable a liquid medium, for example, in a haloalkane, such as methylene chloride, at a moderately elevated temperature (approximately 40 ° C), to form an acid chloride, which is then converted into an amide by treatment with ammonia or an appropriate amine, In this case, a solvent such as benzene or toluene is used at a low temperature, for example, from -5 to 10 C / and then heated and the temperature is maintained at room temperature or slightly higher, for example. 30-40 ° C, I. Alternatively, acrylamide can be obtained as follows. Mixed anhydride is obtained by treating acrylic acid with ethyl chloroformate in the presence of a tertiary amine, such as triethylamine, in an appropriate liquid reaction medium, such as chloroform or toluene at a low temperature of from -5 to 10 ° C, followed by heating and maintaining the temperature at room temperature. or slightly higher to ensure complete reaction. The resulting anhydride mixture is further treated with ammonia or a suitable amine to form the amide. Carboxamides with a structure corresponding to formula (I) can be used to regulate leupo genesis in warm-blooded animals, such as, for example, indoor animals. Animals at the zoo, animals cultivated in the process of meat livestock, animals covered with hair, including dogs , cats, minks, sheep, goats, pigs, cattle, horses, mules, donkeys, monkeys and poultry. This effect is achieved by administering to the animal an effective amount of one or a mixture of two or more carboxamides through the mouth or outside the gastric tract. These substances can be administered alone or as ordinary pharmaceutical active ingredients. drugs. The composition for inhibiting lipogenesis in warm-blooded animals contains carboxamide corresponding to formula (I), as well as a carrier acceptable from a pharmaceutical point of view. The method of inhibiting lipogenesis in warm-blooded animals consists of administering to an animal an effective amount of a substance with formula (I) or a composition containing this substance. Substances and compositions containing these compounds may be administered by mouth or by any convenient method, such as infusion through a probe, intubation, feed and water for an animal, as an additive to the food and as a composition specifically intended for administering the drug. Suitable compositions include such forms as solutions, suspensions, dispersions, emulsions, tablets, large pills, powders, granules, capsules, syrups and elixirs. For parenteral administration, they may be in the form of a solution, suspension, dispersion or emulsion. They can be introduced in the form of an implant or in the form of a drug with controlled resorption. Inert and family-acceptable carriers may be used, such as water, edible oil, gelatin, lactose, starch, magnesium stearate, talc or gum, and they may be used alone or in combination. The dosage of carboxamide required to inhibit lipogenesis will depend on the use of one or another specific carboxamide, as well as the particular animal exposed to the preparation. However, in general, satisfactory results are obtained with the introduction of carboxamides at a dosage of about 1-500 mg per 1 kg of body weight of the animal. Carboxamide can be administered as a single dose or as successively taken throughout the day and doses taken over a period of several days. For a particular animal, a special dosage regimen should be coordinated according to individual need, one way or another specifically used by the carboxamide or carboxamides, as well as the professional opinion of the person conducting the appointment or control for the administration of the inhibitor. Example 1. 3- (4-Chlorobenzoyl) -oxyrancarboxamide (TRANS) (1). 3- (4-Chlorobenzoyl) -acrylic acid (1A) is obtained as a white crystalline solid with mp. 157-158 ° C by the alkylation reaction of Friedel-Crafts, chlorobenzene with maleic anhydride. 21 g of phosphorus pentachloride is added to a slurry of 21 g of the product (lA) in 100 ml of methylene chloride. The resulting homogeneous yellow solution is distilled off at 40 ° C, and the residue is subjected to extraction with benzene. After cooling the benzene solution, the corresponding P acids (1 V) are obtained. M.p. 96-970С. Yield (1 V) 20.7 g, 90%. The product (1 V) is dissolved in 100 ml of benzene, ammonia is passed into the solution. The temperature of the reaction mixture increases from 30 to 55 ° C. The resulting precipitate is separated and washed with water, the residue after recrystallization from chloroform is 3- (4-chlorobenzoyl) -acrylamide (1c) as a white crystalline mass, m.p. with decomposition). Yield 8.0 g, 82%. A solution of 3.7 g of the product (1 C), 4 ml of 30% hydrogen peroxide and 5 ml of 0.1 n. aqueous solution of sodium hydroxide in 100 ML of methanol at | Warm up to, and then cool to 25 ° C for 2 hours. The precipitate formed is collected and washed with ethanol to obtain the product (1) as a white solid with mp 218-219 ° C. Yield 3.5 g, 89%. Analysis. Calculated,%: C 53.3; H 3.5: N 6 Found: C 53.4; H3.5- .N6.1 Example 2. 3- (4-Chlorobenzoyl -N, N-dimethyloxyrancarboxamide (tra (2). A solution of 21 g of product (1 -A) 200 chloroform is cooled to. Then 14 are added to it ml of triethylamine and then 300 ml of toluene. To this mixture the temperature of which is maintained at 10 ° C is added dropwise 10 ml of ethyl chloroformate. The temperature of the mixture is raised to 20 ° C and maintained at this level for 1 h. The mixture is then cooled. 10 ° C and a solution of 5 g of dimethylamine in 100 ml of toluene is slowly added to the solution at a temperature of 10 ° C. Dimethylamine gas is then passed into The mixture is filtered until the solvent is distilled off from the filtrate to obtain a solid product, which is dissolved in methylene chloride. The solution is washed with water, the solvent is evaporated and, after recrystallization from ethyl acetate, the corresponding N, N-dimethylamide (2 A) is obtained in as a yellow solid with a melting point of 117-118 ° C. Yield 6., O g, 38%. The product (2) is in the form of a white solid with mp. 103-104 ° C is obtained by means of peroxide oxidation of the product (2A) according to Example 1. Yield 4.0 g, 65%. Analysis. C, 56.8; H 4.7j N 5.5 Calculated,% Found,%: C 56.7-H 4.8; N Primerz. 3- (4-Chlorobenzoyl) -N-methyloxyrancarboxamide (3) -. The product (3) is obtained in the form of a white solid with so pl. 160lei C 4e (4-chlorophenyl) -N-methyl-4-oxo-2-bchtenamide by oxidation with hydrogen peroxide in accordance with Example 1. The product {3 A) is obtained from the corresponding acrylic acid and monomethyl, min according to the procedure described in example 2. Yield of compound (3) 2.5 g, 50%. Analysis. Calculated,%: C 55.1; H 4.2; N, 5.9; Found: C, 55.2; H 4.2j N 5.8 Example 4. 3- (3,4-Dichlorobenzoyl) -oxyrancarboxamide (4). 28 ml of trecethylamine are dissolved in 600 ml of chloroform, and then 49 g of 3- (3,4-dichlorobenzoyl) -acrylic acid is added. The resulting solution is cooled to and added with 42 g of ethyl chloroformate. The mixture is heated to 20 ° C, stirred for 1 hour, cooled to and the gaseous ammonia is passed into the solution at a constant temperature of 0 ° C until the evolution of reaction heat stops. The resulting precipitate is collected, washed with water and then with acetone to obtain 4- (3,4-dichlorophenyl) -4-oxo-2-butenamide (4 A), white solid, m.p. 208 ° C (with decomposition). The output of 18.0 g, 37%. The product (4) is obtained in the form of a white solid product, so pl. ISS-ieT C, by oxidation (4 A) with hydrogen peroxide in the manner described in paragraph 1. Yield 1.0 g, 8%. Analysis. Calculated,%: C 46.2j H 2.7; N 5.4. Found,%: C 46.2; H 2.6; N 5.4 Examples 5 and 6. In accordance with the procedures described in Example 1, from the corresponding starting materials, 3- (4-methylbenzoyl) -oxyrancarboxamide (5) is obtained in the form of a white-colored product with mp. 209-210 C. Yield 5.0 g, 92%. Analysis. Calculated,%: C 64,4j H 5,4 t-ft-t l ch. f Of i. and and / About Found,%: C 64.3; H 5,5 j N 6,8 3- (Benzoyl) -oxyrancarboxamide (6), in the form of a white solid so pl. 174-175 C. Yield 2.0 g, 30%. Analysis. Calculated,%: C, 62.8; H 4.7 N 7.3. Found,%: C 62.9, - H 4.8; N 7.3. Example 7. 3- (4-Chlorobenzoyl) N- (1-methylethyloxyrancarboxamide) The starting material 4- (4-chlorophenyl) N- (1-methylethyl) -4-oxo-2-butenamide 7 A) is prepared in accordance with the residue, in previous rimers by treating the product 1A) with ethyl chloroformate and riethylamine in toluene with the addition of isopropylamine in toluene at solution. The product (7 A) is obtained in the form of a substance with T.nrf. 162-163 C. The yield of 8.0 g, 50%. This product is converted into a product (7) by treatment with hydrogen peroxide in accordance with the procedure described in example 1, product 7 is obtained in the form of a solid with mp. 128-129 C. Yield 1.0 g, 65%. Analysis,
Calculated,%: C 58.3: H 5.2- N 5; Found,%: C 58.2; H 5.3; N 5.1 Example 8. 3- (4-Nitrobenzoyl) -oxyrancar6oxamide (8).
22 g of 3-benzoyl acrylic acid, crushed to fine powder, are added in portions of 1 g to 11 g of fuming 90% nitric acid with stirring for 30 minutes at a temperature, and then the mixture is heated before, after which, the temperature increases. until, until a clear solution is obtained. After that, the mixture is poured on ice and the resulting solid is filtered off, washed with water, dried (with MgSO4) and the product is isolated by recrystallization from ethyl alcohol, resulting in 3- (4-nitrobenzoyl) -acrylic acid (8 A), t .pl. 199-201 ° C. Yield 3.0 g, 32%.
The product (FOR) is treated with ammonia in accordance with the procedure described in Example 2 to obtain the corresponding amide {8 in). The yield of 9.8 g, 45%.
The product (8c) is converted to the product (8), a solid with so pl. 165-167 ° C, by treatment with hydrogen peroxide in accordance with the procedure described in example 1. Output 0.8 g, 45%.
Analysis.
Calculated,%: C 50.9- H 3.4 N 11.9
 Found%: C 50.9 N 3.4N 12.1
Example 9. 3- (4-Chlorobenzoyl) -N- (2-propenyl) -oxyrancarboxamide.
The product (9) is obtained in the form of solid substance with so pl. LOT-llV C from the product (1A) and allylamine in accordance with the procedure described in Example 1. Yield 1.4 g, 56%. Analysis.
Calculated,%: with 58.8; H 4.51 N 5.3
Found,%: S. 58.9; H 4.5} N 5.4 Example 10. 4-Chlorophenyl-3- (4-morpholinylcarbonyl) -oxyranylmethanone (10).
Obtained in the form of a solid substance with so pl. 137-139 ° C from the product (1 A) and morpholine by the procedures described in example 1. Yield 2.8 g, 76%. Analysis.
Calculated,%: c 56.8 H 4.7 N 4; Found,%: C 56.8; H 4.8 N 4.7 Example 11. 3- (4-Acetamidobenzoyl) -oxyrancarboxamide (11).
A mixture of 50 g of adetanimide and 38 g of maleic anhydride, ground to a fine powder, is added over 2 minutes, with stirring, to quinine
from 185 g of aluminum chloride in 250 ml of carbon disulfide with, increase the temperature of the mixture until it is stirred for 4 hours. The mixture is allowed to stand for 72 hours, then it is gradually added to the mixture of ice and 6 g of hydrochloric acid. The resulting solid is filtered and boiled with methanol; the mixture is filtered. The filtrate is cooled and filtered to obtain 3- (4-acetamidobenzoyl) acrylic acid (11 A). M.p. 220225 ° C. The yield of 11.0 g, 95%.
The product (11A) is converted into the form of a substance (11), which is a white solid mass with m.p. 206-207 seconds
in accordance with the procedures described in example 1. Yield 2.5 g, 50%.
-g
Analysis.
Calculated,%: C 58.1; H 4.8; N 11.3
Found,%: C 58.0; H 4.9; N 11.5
Examples 12-17. Using the procedures of examples 4 and 1, obtain the following compounds:
12.3- (4-Methoxybenzoyl) -oxyrancarboxamide (trans).
Yield 7.5 g, 70%, so pl. 172-173 S.
Analysis.
Calculated,%: C 59.7; H 5.0; N 6.3
Found,%: C59.8; H5.0; N 6.3
13.3- (4-Chlorobenzoyl) -N- (2-propinyl) -oxyrancarboxamide (trans) f
The output of 3.3 g, 89%, so pl. 171-. 173, Analysis. Calculated,%: C 59.2; H 3.8;

Found,%: C 59.0; H 3.8;
N 5,6
14.3- (4-Bromobenzoyl) -oxyrancarboxamide (trans).
Yield 0.7 g, 13%, so pl. 210-211 C. Analysis.
Calculated,%; C44.4; NZ, 0; N 5.2
Found, i: C 44,5; H3.0; N 5.2.
15. 3- (4-Fluorobenzoyl) -oxyrancarboxamide (trans).
Yield 2.9 g, 74%, so pl. 188.5190,.
Analysis. “. Calculated,%: C57.4; H3.8; N 6.7
Found,% C 57.3; H 3.9; N 6.7
16. 3- (2,4-Dichlorobenzoyl) -oxyrancarboxamide (trans).
yield 0.4 g, 31%, so pl. 121-122p. Analysis.
Calculated,%: C 46.2; H 2.7; N 5.4

权利要求:
Claims (1)
[1]
Found,%: C 46.2; H 2.8; N 5.3 17. 3- (3-Trifluoromethylbenzoyl) -ok Sirancarboxamide (trans). Yield 0.7 g, 66%, so pl. 122-123 ° Analysis. ,: C 51.0; H 3.1; It is calculated that N 5.4 C 51.2; H 3.1; Found,% N5.3. , Example 18. Test methods demonstrating inhibition of lipogezis. The effectiveness of the compounds obtained in accordance with the present invention is assessed by immersing some time samples of the liver of living or adipose tissue into a liquid medium containing radioactive glucose and a chemical test substance, then extracting the lipid from the treated tissue and Radioactive carbon uptake is determined using a flash counter. These tests are carried out both on liver tissue and on adipose tissue, since in some animals, lipogenesis occurs primarily in the liver tissue, while in other animals, lipogenesis occurs in adipose tissue. The animals to be tested were pigs, chickens and sheep. Tissue sections (200 mg of liver and 150 adipose tissue) are incubated at 37 ° C for 2 hours with shaking in 3 ml of Krebs-Ringer bicarbonate solution containing 0.5N. the concentration of calcium ions, 60 µmol glucose, 0.5 micro Curie glucose 14c and 300 micro units of insulin and 5% dimethyl sulfoxide (DMSO). Test compounds are added as a suspension in DMSO at a concentration of 100 µg per ml of incubated mixture. The incubation is finished after adding 0.25 ml of 1N. sulfuric acid. The resulting mixture is extracted with a total amount in 25 ml of chloroform and methanol (2: 1 by volume). The extracts are washed, air dried and examined using a liquid meter with a 15 ml counting liquid component. These tests are carried out three times and followed by control tests in which all the ingredients, as well as the multiplicities and conditions were the same, except that did not enter the component under study. Based on the data obtained, a calculation was made of the percentage inhibition of lipid synthesis in the tested compounds in each of the cases. Product 1 was studied for all animals for its inhibitory effect. The remaining compounds were only used for their effects on pigs. On the basis of data and other experiments, it was determined that the tissues of the liver of pigs have little lipogenic activity. Similarly, from these and other experiments, it was concluded that adipose pig tissue uses glucose for lipogenesis, and is also the main site for fatty acid synthesis. The test data obtained using adipose tissue and glucose are given below as a percentage of inhibition of lipogenesis compared with the results obtained from control tests in which only the test compounds are missing. Product Percent Inhibition 94 In chickens, the main site of the synthesis fatty acid is the liver. Compound 1 inhibited liver glucose by 54%. WHAT concerns sheep, they have a greater amount of glucose enters the liver with the formation of lipids compared with adipose tissue. Product 1 inhibits (by 15%) glucose access to the liver and adios tissue (by 65%). The invention The method of obtaining 3- (benzoyl) -okirancarboxamides of general formula. O / K. g -co-dH-CH-do-w. Each of the R and Rj radicals, on its own, is hydrogen, methyl, ethyl, propyl, propyl or propynyl, or together with the nitrogen atom between them, morpholinyl; 11 Rj is iodide, chlorine, bromine, fluorine, methyl, methoxy, nitro: or acetamido; Cl is hydrogen, chlorine or trifluorome Re-hydrogen or chlorine, characterized in that acridamide of the general formula ff Ri / VdO-OH CH-CO- N / Z 20662 12 where they have the above values, is reacted with 2.2 molar equivalents of hydrogen peroxide in the presence of 2.8 mol.% Alkali metal hydroxide at a temperature of 25-50 ° C. Sources of information taken into account in the examination to Fuson R. Reactions of organic compounds. M., Himi, 1966, p.200.

类似技术:

---

公开号 | 公开日 | 专利标题

---

JP6449845B2|2019-01-09|Sodium channel modulator for the treatment of pain

---

US3949085A|1976-04-06|Anabolic-weight-gain promoting compositions containing isoflavone derivatives and method using same

---

AU2013292046C1|2018-03-15|Novel 5-aminotetrahydroquinoline-2-carboxylic acids and use thereof

---

DE60036816T2|2008-07-17|NEW ESTERS AS SELECTIVE COX-2 INHIBITORS FROM INDOLAL CANNULES AND NEW AMIDS FROM INDOLAL CYLAMINES

---

SU728713A3|1980-04-15|Method of preparing salicylanilide derivatives

---

EA018195B1|2013-06-28|Substituted 2-[2-|ethylamino]alkaneamide derivatives and their use as sodium and/or calcium channel modulators

---

SU820662A3|1981-04-07|Method of preparing-3-|-oxyrancarboxamides

---

JPWO2007086354A1|2009-06-18|New histidine derivatives

---

US3907830A|1975-09-23|Isoflavone derivatives

---

Troshin et al.2018|Parameters of acute toxicity of the Ferro-Quin iron-sorbitol-protein complex

---

RU2284993C2|2006-10-10|2-ethyl-6-methyl-3-oxypyrodine salts with organic carboxylic acids possessing anxiolytic, antidepressive, antihypoxic, anti-amnestic and anti-oxidative activity and method for their preparing

---

EP0293899B1|1993-10-13|Phenolic thioalkylamides as inhibitors of 5-lipoxygenase

---

RU2503671C1|2014-01-10|-2-[|AMINO]-4-|-4-OXOBUT-2-ENOIC ACIDS, HAVING ANALGESIC ACTIVITY

---

CA1240326A|1988-08-09|2-|-AND 2-|- 3-|-PHTALIMIDINES

---

EP3818046A1|2021-05-12|Lactate enhancing compounds and uses thereof

---

WO2012138255A2|2012-10-11|Tricyclic derivatives of ν,ν'-substituted 3,7-diazabicyclo [3.3.1]nonanes, having a pharmacological activity, and medicaments based thereon

---

EA008664B1|2007-06-29|New n-hydroxy -4-|-benzenesulphonamide solvates

---

RU2679450C2|2019-02-11|2-|-4-|-1-|but-2-ene-1,4-dione hydrochloride with hemostatic activity

---

RU2549572C2|2015-04-27|2-|amide of 2-|-4-oxo-4-phenyl-2-butenoic acid, having analgesic effect

---

RU2663624C1|2018-08-07|4-|-2-{2-[2-oxo-|-ethylidene]hydrazinyl}-4-oxobut-2-enoate sodium with hemostatic activity

---

Luis et al.2014|Synthesis and preliminary ex vivo evaluation of the spasmolytic activity of 1, 3-thiazolium-and 1, 3, 4-thiadiazolium-5-methylthio-and 5-tioacetate derivatives

---

HU199440B|1990-02-28|Process for producing morpholine derivatives and pharmaceutical compositions comprising the compounds

---

RU2537381C1|2015-01-10|N-|amides of 4-aryl-4-oxo-2-|but-2-enoic acids, having analgesic activity

---

RU2664453C1|2018-08-17|Derivative of 3-hydroxypyridine with anxiolytic and nootropic effect

---

RU2756449C2|2021-09-30|Linear substituted glyproline with antidepressant and analgesic effect

同族专利:

---

公开号 | 公开日

---

IE780531L|1978-09-17|

---

FR2383934B1|1980-06-20|

---

ZA781542B|1979-03-28|

---

AU518343B2|1981-09-24|

---

JPS53116345A|1978-10-11|

---

NL7802798A|1978-09-19|

---

SE7801959L|1978-09-18|

---

PL205323A1|1979-08-27|

---

US4091221A|1978-05-23|

---

LU79234A1|1978-10-17|

---

IT1094959B|1985-08-10|

---

FR2383934A1|1978-10-13|

---

DE2811256A1|1978-09-21|

---

IE46582B1|1983-07-27|

---

BE864916A|1978-09-15|

---

AU3416478A|1979-09-20|

---

GB1597872A|1981-09-16|

---

IT7821258D0|1978-03-15|

---

US4127656A|1978-11-28|

---

DK117378A|1978-09-18|

---

DD136743A5|1979-07-25|

---

PL115936B1|1981-05-30|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US2850509A|1958-09-02|Diketo-io |JPS6155509B2|1978-09-30|1986-11-28|Taisho Pharma Co Ltd|

---

JPH0154348B2|1979-02-27|1989-11-17|Taisho Pharma Co Ltd|

---

US4235923A|1979-05-04|1980-11-25|Shell Oil Company|Esters of 3-substituted-2-oxiranecarboxylic acids as lipogenesis inhibitors|

---

US4271185A|1980-01-25|1981-06-02|Shell Oil Company|Heterocyclyl 2--2-hydroxy-1-methyl)ethylamino)ethyl ketones as lipogenesis inhibitors|

---

DE3927370A1|1989-08-19|1991-02-21|Bayer Ag|METHOD FOR PRODUCING CLAUSENAMIDE AND NEOCLAUSENAMIDE AND THEIR DERIVATIVES|

---

CN106316876B|2015-06-29|2018-04-27|中国医学科学院医药生物技术研究所|β-carbonyl acrylamides, its preparation method and application|

法律状态:

优先权:

---

申请号 | 申请日 | 专利标题

---

US05/778,536|US4091221A|1977-03-17|1977-03-17|3-oxiranecarboxamides|

---